✦ LIBER ✦

Pioneer oral nutraceutical formula (PLP10) for the treatment of relapsing remitting multiple sclerosis: A randomized, double-blind, placebo-controlled proof-of-concept clinical trial

✍ Scribed by Patrikios, I.S.; Loukaides, G.N.; Ntzani, E.E.; Pantzaris, M.C.

Book ID: 127193678
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 211 KB
Volume: 2
Category: Article
ISSN: 2213-4344
DOI: 10.1016/j.phanu.2013.11.038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LB003-MON ORAL NUTRACEUTICAL FORMULA (PL

LB003-MON ORAL NUTRACEUTICAL FORMULA (PLP10) FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS: DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

✍ I.S. Patrikios; M.C. Pantzaris; G.N. Loukaides; E.E. Ntzani 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Magnetic resonance imaging results of th

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis

✍ David K. B. Li; Donald W. Paty 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

The PRISMS (Prevention of Relapses and Disability by Interferon-␤1a Subcutaneously in Multiple Sclerosis) trial was a doubleblind, randomized, multicenter, phase III, placebo-controlled study of interferon-␤1a in 560 patients from 22 centers in 9 countries with clinically definite or laboratory-supp

Oral laquinimod in patients with relapsi

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

✍ Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 307 KB

NORdic trial of oral Methylprednisolone

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

✍ Per Soelberg Sorensen; Svein Ivar Mellgren; Anders Svenningsson; Irina Elovaara; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 175 KB

FP36-WE-02 Clinical outcomes of short-co

FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

✍ G. Giovannoni; G. Comi; S. Cook; K. Rammohan; P. Rieckmann; P. Soelberg-Sørensen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

PO10-TU-39 Safety and tolerability of sh

PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

✍ S. Cook; P. Vermersch; G. Comi; G. Giovannoni; K. Rammohan; P. Rieckmann; P. Soe 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB